SCHEMBL31727906

SCHEMBL31727906

C[C@H](Oc1ccc(-c2cccc(Cl)c2Cl)c2ncnc(N)c12)c1ncn(C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 3/20 0.36
▸ HTR7 P34969 3/20 0.36
▸ HTR6 P50406 3/20 0.36
▸ SRC P12931 4/20 0.33
▸ ABL1 P00519 3/20 0.33
▸ EPHB4 P54760 3/20 0.33
▸ PIK3CD O00329 3/20 0.33
▸ EGFR P00533 2/20 0.33
▸ HCK P08631 2/20 0.33
▸ KDR P35968 2/20 0.33
▸ PIK3CA P42336 2/20 0.33
▸ PIK3CB P42338 2/20 0.33
▸ MTOR P42345 2/20 0.33
▸ PIK3CG P48736 2/20 0.33
▸ PRKDC P78527 2/20 0.33
▸ PI4KB Q9UBF8 2/20 0.33
▸ PTPN11 Q06124 4/20 0.32
▸ NUDT1 P36639 2/20 0.32
▸ HTR1A P08908 2/20 0.32
▸ HTR2A P28223 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31727946 1.00 DRD2 (0.36) DRD2HTR7HTR6SRCABL1
SCHEMBL31727720 0.83 EPHB4 (0.33) DRD2HTR7HTR6SRCABL1
SCHEMBL31728022 0.83 SRC (0.33) DRD2HTR7HTR6SRCABL1
SCHEMBL31728988 0.80 EPHB4 (0.34) DRD2HTR7HTR6SRCABL1
SCHEMBL31728407 0.79 JAK2 (0.33) SRCABL1EPHB4PIK3CDEGFR
SCHEMBL31728708 0.79 JAK2 (0.33) SRCABL1EPHB4PIK3CDEGFR
SCHEMBL31728377 0.79 JAK2 (0.33) DRD2HTR7HTR6HTR1AHTR2A
SCHEMBL31728811 0.78 SRC (0.36) SRCABL1EPHB4PIK3CDEGFR
SCHEMBL31728350 0.78 SRC (0.39) SRCABL1PIK3CDEGFRKDR
SCHEMBL31728979 0.78 SRC (0.39) SRCABL1PIK3CDEGFRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback